Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pere Gascon

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Targeted Oncology|January 20, 2012
Presently available biosimilars in hematology-oncology: G-CSFPere Gascon
Therapeutic Advances in Hematology|December 2, 2015
The evolving role of biosimilars in haematology-oncology: a practical perspectivePere Gascon
World Journal of Gastroenterology|November 9, 2007
Is there a genetic signature for liver metastasis in colorectal cancer?Cristina Nadal, Joan Maurel, Pere Gascon
Future Oncology (London, England)|July 25, 2019
Knowledge and awareness of biosimilars among oncology patients in Colorado, USARovshan M Ismailov, Zaytuna D Khasanova, Pere Gascon
European Journal of Cancer Care|April 11, 2019
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF studyMatti Aapro, Andriy Krendyukov, Nadja Höbel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2020
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables CurePaul Cornes, Pere Gascon, Arnold G Vulto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
Hematology, Transfusion and Cell Therapy|February 24, 2021
Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USARovshan M Ismailov, Dyana T Saenz, Pere Gascon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 23, 2006
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapyMark Vincent, George Dranitsaris, Sunil Verma, et al.
Journal of Pain and Symptom Management|February 20, 2016
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry StudyAlexander Molassiotis, Paul H Lee, Thomas A Burke, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Targeted Oncology|January 20, 2012
Presently available biosimilars in hematology-oncology: G-CSFPere Gascon
Therapeutic Advances in Hematology|December 2, 2015
The evolving role of biosimilars in haematology-oncology: a practical perspectivePere Gascon
World Journal of Gastroenterology|November 9, 2007
Is there a genetic signature for liver metastasis in colorectal cancer?Cristina Nadal, Joan Maurel, Pere Gascon
Future Oncology (London, England)|July 25, 2019
Knowledge and awareness of biosimilars among oncology patients in Colorado, USARovshan M Ismailov, Zaytuna D Khasanova, Pere Gascon
European Journal of Cancer Care|April 11, 2019
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF studyMatti Aapro, Andriy Krendyukov, Nadja Höbel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2020
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables CurePaul Cornes, Pere Gascon, Arnold G Vulto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
Hematology, Transfusion and Cell Therapy|February 24, 2021
Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USARovshan M Ismailov, Dyana T Saenz, Pere Gascon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 23, 2006
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapyMark Vincent, George Dranitsaris, Sunil Verma, et al.
Journal of Pain and Symptom Management|February 20, 2016
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry StudyAlexander Molassiotis, Paul H Lee, Thomas A Burke, et al.
Pageof 4